We verified the efficacy of anti-IL-1R1 in vivo by measuring the relative expression of IL-1-responsive genes and saw a significant reduction in the expression of Il6, Il1b and Ptgs2 in tumours from anti-IL-1R1-treated mice relative to IgG-treated mice (Supplementary Fig. 2k). This evidence concerns the gene IL6 and neoplasm.